Propafenone

Publisher Website
Google Scholar
Abstract
PROPAFENONE HYDROCHLORIDE (Rythmol) is an antiarrhythmic drug that has been extensively used in Europe and has recently been approved for oral use in the United States for the management of ventricular arrhythmias. The drug (2′-[3-(propylamino)-2-(hydroxy)-propoxy]-3-phenylpropiophenone hydrochloride) is a sodium-channel blocker whose kinetics of interaction with cardiac sodium channels are similar to those of flecainide and encainide. Like these agents, propafenone suppresses nonsustained ventricular arrhythmias, whereas its effect is less consistent in patients with sustained ventricular arrhythmias. In addition, propafenone has β-adrenergic—antagonist properties that may be clinically relevant in some patients. Interpreting the relation between its plasma concentration and its action . . .